Prescriptions for the diabetes drug Ozempic and its weight loss counterpart, Wegovy, have skyrocketed in the past year. Doctors and patients have begun to notice another effect of these drugs: They appear to reduce cravings for alcohol, nicotine and opioids. Several clinical trials are underway to understand how these drugs alter people's drinking and smoking habits. 💊 The active ingredient in Ozempic and Wegovy is semaglutide, a GLP-1 drug. 💊 Studies show that GLP-1 drugs can reduce dopamine release in the region of the brain that controls motivation 💊 The National Institute on Drug Abuse advises against using Ozempic or Wegovy to treat addictions because it might not work on everyone, and there's a risk of pancreatitis. 💊 More research could lead to a GLP-1 medication that treats addiction better than diabetes. |
No comments:
Post a Comment